GlassScriptPhysician profile
Holly Rose Weis
NPI 1568751352
$1,901.09
in general payments reported to CMS, 2019-2025
21 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $320 · 2023: $436 · 2024: $454 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $229.87 | 2022-2025 | Rocklatan, Tryptyr |
| Novartis Pharmaceuticals Corporation | $229.60 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $226.81 | 2022-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $187.98 | 2021 | |
| Amgen INC. | $141.38 | 2024-2025 | Tepezza |
| Rxsight INC | $140.78 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $128.37 | 2024 | Xdemvy |
| Astellas Pharma US INC | $95.52 | 2024-2025 | Izervay |
| Harrow Eye, LLC | $86.97 | 2024 | Vevye |
| Abbvie INC. | $74.81 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $64.94 | 2023-2024 | Acthar |
| Tearlab Corp | $49.15 | 2022 | |
| Thea Pharma INC. | $48.81 | 2023 | Iyuzeh |
| Bausch & Lomb Americas INC. | $44.24 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $31.48 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $28.40 | 2022 | |
| Sight Sciences, INC. | $21.32 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Kala Pharmaceuticals, INC. | $19.34 | 2021 | |
| Apellis Pharmaceuticals, INC. | $18.40 | 2025 | Syfovre |
| Horizon Therapeutics Plc | $17.54 | 2023 | Tepezza |
| Biotissue Holdings INC. | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Weis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.